Related Experiment Video
Updated: Jul 8, 2025

JUMPn: A Streamlined Application for Protein Co-Expression Clustering and Network Analysis in Proteomics
Published on: October 19, 2021
Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven
Won-Min Song1,2,3, Abdulkadir Elmas1,2,3, Richard Farias1,4
1Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, 1425 Madison Avenue, New York, NY, 10029, USA.
Abstract:
Global proteomic data generated by advanced mass spectrometry (MS) technologies can help bridge the gap between genome/transcriptome and functions and hold great potential in elucidating unbiased functional models of pro-tumorigenic pathways. To this end, we collected the high-throughput, whole-genome MS data and conducted integrative proteomic network analyses of 687 cases across 7 cancer types including breast carcinoma (115 tumor samples; 10,438 genes), clear cell renal carcinoma (100 tumor samples; 9,910 genes), colorectal cancer (91 tumor samples; 7,362 genes), hepatocellular carcinoma (101 tumor samples; 6,478 genes), lung adenocarcinoma (104 tumor samples; 10,967 genes), stomach adenocarcinoma (80 tumor samples; 9,268 genes), and uterine corpus endometrial carcinoma UCEC (96 tumor samples; 10,768 genes). Through the protein co-expression network analysis, we identified co-expressed protein modules enriched for differentially expressed proteins in tumor as disease-associated pathways. Comparison with the respective transcriptome network models revealed proteome-specific cancer subnetworks associated with heme metabolism, DNA repair, spliceosome, oxidative phosphorylation and several oncogenic signaling pathways. Cross-cancer comparison identified highly preserved protein modules showing robust pan-cancer interactions and identified endoplasmic reticulum-associated degradation (ERAD) and N-acetyltransferase activity as the central functional axes. We further utilized these network models to predict pan-cancer protein regulators of disease-associated pathways. The top predicted pan-cancer regulators including RSL1D1, DDX21 and SMC2, were experimentally validated in lung, colon, breast cancer and fetal kidney cells. In summary, this study has developed interpretable network models of cancer proteomes, showcasing their potential in unveiling novel oncogenic regulators, elucidating underlying mechanisms, and identifying new therapeutic targets.
Insights
This study uses proteomic network analysis across seven cancers to identify key cancer pathways and regulators. It reveals conserved protein modules and validates new therapeutic targets like RSL1D1, DDX21, and SMC2.
Area of Science:
- Proteomics
- Systems Biology
- Cancer Research
Background:
- Global proteomic data from mass spectrometry (MS) can elucidate cancer functional models.
- Integrative proteomic network analyses were performed on 687 cases across 7 cancer types.
Discussion:
- Protein co-expression network analysis identified disease-associated pathways.
- Comparison with transcriptome networks revealed proteome-specific cancer subnetworks.
- Cross-cancer analysis identified conserved protein modules and central functional axes: ERAD and N-acetyltransferase activity.
Key Insights:
- Developed interpretable network models of cancer proteomes.
- Identified novel pan-cancer protein regulators (RSL1D1, DDX21, SMC2) for disease-associated pathways.
- Experimental validation confirmed the role of predicted regulators in various cancer and fetal cells.
Outlook:
- Proteomic network models offer potential for discovering oncogenic regulators.
- This approach can elucidate cancer mechanisms and identify new therapeutic targets.
- Further research can leverage these models for precision oncology.
Related Concept Videos
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Protein-protein Interfaces
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

